OverviewSuggest Edit

Aprogen is a biologics platform company focused on developing and manufacturing biosimilar products, protein drugs, and bispecific antibodies. It develops various recombinant antibody drugs aimed to minimize side-effects or immunogenicity for long-term treatment.

Latest Updates

Employees (est.) (Sept 2021)32(-37%)
Cybersecurity ratingDMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Aprogen Financials and Metrics

Summary Metrics

Founding Date


Aprogen total Funding

$16.7 m

Aprogen latest funding size

$16.7 m

Time since last funding

2 years ago

Aprogen investors

Aprogen's latest funding round in December 2019 was reported to be $16.7 m. In total, Aprogen has raised $16.7 m
Show all financial metrics

Aprogen Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Aprogen Online and Social Media Presence

Embed Graph

Aprogen Frequently Asked Questions

  • When was Aprogen founded?

    Aprogen was founded in 2000.

  • How many employees does Aprogen have?

    Aprogen has 32 employees.

  • Who are Aprogen competitors?

    Competitors of Aprogen include Bioceros, Enteris BioPharma and AC Immune.